Over the last 6 months PAA had both Michael & John in CEO and COO positions to deliver the activity set. Nothing has changed as far as deliverables go, in fact I expect the workload will only increase over the next 6 - 12 months.
So PharmAust will be needing to recruit.
But given the ASX release clearly has John as interim CEO, is the intention to hire a new CEO, with John in a caretaker role , returning to COO once the hire is complete.
If that is the case, PharmAust may well attract a high profile & high performing biotechnology CEO. The results to date, ODD designation … and the chance to lead commercialising a drug with a mechanism of action that may revolutionise care across neurodegenerative disease. Could be very tempting for the right high flyer.
Every problem creates an opportunity…
Let’s see how this pans out.
Ann: Resignation of Dr Michael Thurn & appointment of John Clark, page-234
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.020(8.89%) |
Mkt cap ! $81.16M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.5¢ | $331.9K | 1.617M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 440882 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 12736 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |